Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Jul 26, 2024 → Nov 1, 2027
NCT ID
NCT06433557About Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections is a phase 2 stage product being developed by Ascendis Pharma for Achondroplasia. The current trial status is active. This product is registered under clinical trial identifier NCT06433557. Target conditions include Achondroplasia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06433557 | Phase 2 | Active |
Competing Products
20 competing products in Achondroplasia